Compare · CHPT vs EW
CHPT vs EW
Side-by-side comparison of ChargePoint Holdings Inc. (CHPT) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- CHPT operates in Consumer Discretionary, while EW operates in Health Care - the two are in different parts of the market.
- EW is the larger of the two at $51.87B, about 317.9x CHPT ($163.2M).
- Over the past year, CHPT is down 49.5% and EW is up 17.3% - EW leads by 66.7 points.
- CHPT has been more active in the news (10 items in the past 4 weeks vs 6 for EW).
- Both have 25 recent analyst ratings on file.
- Company
- ChargePoint Holdings Inc.
- Edwards Lifesciences Corporation
- Price
- $6.29+3.11%
- $90.07-1.89%
- Market cap
- $163.2M
- $51.87B
- 1M return
- -4.48%
- +5.04%
- 1Y return
- -49.48%
- +17.26%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NYSE
- IPO
- 2019
- News (4w)
- 10
- 6
- Recent ratings
- 25
- 25
ChargePoint Holdings Inc.
ChargePoint Holdings, Inc. provides electric vehicle (EV) charging networks and charging solutions in the United States. It offers a portfolio of hardware, software, and services for commercial, fleet, and residential customers. The company was founded in 2007 and is headquartered in Campbell, California.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest CHPT
- ChargePoint and Onvo Expand Highway Fast Charging Across the Northeastern U.S.
- ChargePoint and Optimus Energy Solutions Partner to Build New Fast Charging Network in the Eastern U.S
- ChargePoint Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- ChargePoint Added to Membership of Russell 2000® Index
- CCXO Singh Jagdeep Ca sold $69,350 worth of shares (9,719 units at $7.14), decreasing direct ownership by 5% to 187,846 units (SEC Form 4) (tax liability)
- CRO Vice John David sold $29,053 worth of shares (4,072 units at $7.13), decreasing direct ownership by 2% to 171,507 units (SEC Form 4) (withholding obligation)
- CFO Khetani Mansi sold $58,165 worth of shares (8,152 units at $7.13), decreasing direct ownership by 4% to 179,348 units (SEC Form 4) to satisfy tax liability
- CAO Novruzova Natella Fakhradovna sold $15,996 worth of shares (2,242 units at $7.13), decreasing direct ownership by 7% to 29,315 units (SEC Form 4) (tax withholding)
- President and CEO Wilmer Richard covered exercise/tax liability with 7,631 shares, decreasing direct ownership by 1% to 503,593 units (SEC Form 4)
- General Counsel Batill Eric sold $35,523 worth of shares (4,979 units at $7.13), decreasing direct ownership by 3% to 143,631 units (SEC Form 4) to satisfy tax liability
Latest EW
- CVP, EMEACLA Bruls Annette covered exercise/tax liability with 109 shares, decreasing direct ownership by 0.53% to 20,628 units (SEC Form 4) (for withholding tax)
- CVP, Chief Financial Officer Mistras Theodora was granted 99,920 shares (SEC Form 4)
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,762 worth of shares (619 units at $91.70) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TAVR Lippis Daniel J. covered exercise/tax liability with 377 shares, decreasing direct ownership by 0.93% to 40,034 units (SEC Form 4) to cover taxes
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,577 worth of shares (619 units at $91.40) as part of a pre-agreed trading plan (SEC Form 4)
- Edwards’ Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves
- CEO Zovighian Bernard J sold $45,982 worth of shares (523 units at $87.92) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 11-K filed by Edwards Lifesciences Corporation
- SEC Form 11-K filed by Edwards Lifesciences Corporation
- SEC Form 3 filed by new insider Mistras Theodora